Dall’analisi delle linee guida e della realtà italiana ai vantaggi dell’utilizzo della combinazione enalapril/lercanidipina nel paziente iperteso e diabetico

Pubblicato il: 7 Settembre 2015|

AboutMedicine Spotlight Anno III, N. 19, agosto 2015

Carlo B. Giorda
Direttore SC Malattie Metaboliche e Diabetologia, ASL TORINO 5

Indice

Introduzione
Ipertensione e diabete: fisiopatologia di un’associazione deleteria
Ipertensione e diabete: raccomandazioni e linee guida italiane
La fotografia della realtà assistenziale italiana del diabete e ipertensione negli annali AMD
Il problema dell’aderenza ai trattamenti e le potenzialità delle terapie combinate
Focus sull’associazione ACE-inibitore/calcioantagonista diidropiridinico e in particolare su enalapril/lercanidipina
Bibliografia

QUICK LINKS

SEGUICI SU

SEGUI ABOUTPHARMA SU
www.aboutpharma.com

NOTE LEGALI

CONTATTACI

HPS srl
Milano: Piazza Duca d’Aosta, 12 – 20124 – Tel +39 02 2772 991 (Sede legale)
Roma: Viale dell’Arte, 25 – 00144
PEC hps.srl@legalmail.it | P.IVA 07106000966 | REA MI – 1935962 | Capitale Sociale: €20.000 i.v.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Sempre abilitato

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Durata	Descrizione
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Dall’analisi delle linee guida e della realtà italiana ai vantaggi dell’utilizzo della combinazione enalapril/lercanidipina nel paziente iperteso e diabetico

CONDIVIDI